HEALTH 2.0 ANNUAL CONFERENCE | SAN FRANCISCO, CA | SEPT. 16-18, 2020
By Heather Munro, freelance writer focusing on emerging technology.
It’s a quandary familiar to anyone treating chronic conditions such as depression: Not only do sufferers often delay seeking treatment, when they do, they often have to wait to receive treatment because there aren’t enough qualified professionals accepting new patients.
To help fill this gap, apps for tracking moods, practicing mindfulness, even connecting with online community support have arrived on the scene. And while these solutions do give patients a helpful tool they can use at home to change their behaviors and lifestyle choices—and better manage their condition—the potential to the healthcare industry is even more far-reaching.
Effective digital therapeutics can deliver treatment more cheaply than traditional therapy, saving clinicians valuable time and getting patients much-needed care sooner. But according to McKinsey & Company, a global management consulting firm, clinicians have been slow to adopt and recommend digital therapeutics to their patients.
The reason is twofold. First, there’s a big difference between a fitness tracker that measures your heartbeat and an app that has been approved by the FDA and classified as Software as a Medical Device. To be successful, digital therapeutics must distinguish themselves from the fitness-focused digital health and well-being market while aligning with providers’ and payor’s existing internal processes.
To learn more about a cognitive behavior therapy app currently being developed in this evolving arena, read “Click Therapeutics teams up with Otsuka on digital therapeutic for major depressive disorder” on MobiHealthNews.